{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=elranatamab&page=2", "query": { "intervention": "elranatamab", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=elranatamab&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-07T10:18:32.694Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07280013", "title": "A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma (MM)" ], "interventions": [ { "name": "Cemsidomide", "type": "DRUG" }, { "name": "Elranatamab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "C4 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-02-06", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-06-07T10:18:32.694Z", "location_count": 16, "location_summary": "Gilbert, Arizona • Santa Monica, California • Tampa, Florida + 13 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07280013" }, { "nct_id": "NCT06215118", "title": "A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "Iberdomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2024-02-20", "completion_date": "2028-03-09", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-07T10:18:32.694Z", "location_count": 34, "location_summary": "Coral Gables, Florida • Deerfield Beach, Florida • Doral, Florida + 20 more", "locations": [ { "city": "Coral Gables", "state": "Florida" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Doral", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06215118" }, { "nct_id": "NCT06057402", "title": "Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2023-10-03", "completion_date": "2032-02-22", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-06-07T10:18:32.694Z", "location_count": 14, "location_summary": "Fort Collins, Colorado • Greeley, Colorado • Longmont, Colorado + 7 more", "locations": [ { "city": "Fort Collins", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Greeley", "state": "Colorado" }, { "city": "Longmont", "state": "Colorado" }, { "city": "Longmont", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06057402" }, { "nct_id": "NCT05020236", "title": "A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 944, "start_date": "2021-10-04", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-06-07T10:18:32.694Z", "location_count": 11, "location_summary": "Clovis, California • Fresno, California • Fort Collins, Colorado + 7 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Greeley", "state": "Colorado" }, { "city": "Aventura", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05020236" }, { "nct_id": "NCT06988488", "title": "A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "Mezigdomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2025-10-07", "completion_date": "2027-06-03", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-06-07T10:18:32.694Z", "location_count": 4, "location_summary": "Birmingham, Alabama • New Haven, Connecticut • Hackensack, New Jersey + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06988488" }, { "nct_id": "NCT06504524", "title": "A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 633, "start_date": "2023-09-01", "completion_date": "2024-05-31", "has_results": true, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-06-07T10:18:32.694Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06504524" }, { "nct_id": "NCT06106945", "title": "AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "AZD0305", "type": "DRUG" }, { "name": "Elranatamab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2023-12-05", "completion_date": "2027-08-16", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-06-07T10:18:32.694Z", "location_count": 9, "location_summary": "Duarte, California • Irvine, California • Atlanta, Georgia + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06106945" }, { "nct_id": "NCT05675449", "title": "A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Maplirpacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2022-12-14", "completion_date": "2028-02-29", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-06-07T10:18:32.694Z", "location_count": 31, "location_summary": "Little Rock, Arkansas • Beverly Hills, California • Encino, California + 15 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05675449" }, { "nct_id": "NCT06974786", "title": "Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma, Newly Diagnosed", "Multiple Myeloma (MM)" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "autologous stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 100, "start_date": "2025-08-08", "completion_date": "2033-04", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-07T10:18:32.694Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Denver", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06974786" }, { "nct_id": "NCT06711705", "title": "Elranatamab in Relapsed/Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2024-12-18", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-06-07T10:18:32.694Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06711705" } ] }